近期，全球制药巨头诺和诺德（Novo Nordisk）向新加坡生物技术公司KBP Biosciences（中文名：亨利医药，以下简称“KBP”）及其创始人黄振华提起高达8.3 ...

2月28日，总部设在新加坡的生物科技公司KBP Biosciences Pte. Ltd. （下称KBP）发表声明，回应新加坡国际商事法院（SICC）近期作出的裁决。SICC于2025年2月 ...

Novo Nordisk has agreed a $1.3 billion deal with Singapore’s KBP Biosciences to buy ocedurenone, a drug for uncontrolled hypertension that ties in with its ongoing efforts to expand beyond its ...

SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a recent decision by the Singapore International Commercial Court ("SICC ...

Feb 18 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it ...

The KBP lawyer also shared that while there are other broadcasters on free TV, which he estimated at more than 30 players, they are not producing content like how ABS-CBN did it.

The Danish pharma giant plans to seek $830 million in damages from Singapore-based KBP Biosciences and KBP’s founder and executive chairman, Zhenhua Huang, Ph.D., according to a Feb. 14 ruling ...

Novo Nordisk, best known for blockbuster obesity drug Wegovy, and KBP Biosciences did not immediately respond to a request for comment. Huang was not immediately available for comment. The Danish ...

SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a recent decision by the Singapore International Commercial Court ("SICC"), which ...

Novo Nordisk is seeking up to US$830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it was misled when it bought a new ...